Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation (IXO-01)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01243008|
Recruitment Status : Completed
First Posted : November 17, 2010
Last Update Posted : November 19, 2010
|Condition or disease||Intervention/treatment||Phase|
|Lyme Disease||Drug: Application of SHB001||Phase 1 Phase 2|
In this study two consecutive cohorts will be treated:
- Cohort 1: 8 volunteers
- Cohort 2: 24 volunteers, divided into 3 groups of 8 subjects each
The study will be conducted in the following three phases:
Treatment of cohort 1: The aim is to establish the maximal tolerated dose (MTD) for a local treatment with azithromycin dermal formulation.
- Treatment of cohort 1 with azithromycin dermal formulation and follow up
- Assessment of local safety within the 7 days following the first treatment
- The maximal tolerated dose (MTD) will be determined
Treatment of cohort 2: The aim is to confirm the local tolerance of the selected doses and to evaluate the local skin and plasma concentration of azithromycin after application of SHB001 dermal formulation.
- Treatment of cohort 2 with azithromycin dermal formulation at maximal tolerated dose (MTD), with a dose one or more concentrations lower than maximal tolerated dose (MTD) and with placebo
- Skin biopsies of treated skin areas will be taken for the PK assessment
- Study completion examination
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||32 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Single Centre, Randomized, Investigator Blinded, Placebo-controlled Ascending Dose Study to Assess the Local Safety, the Skin and Plasma Concentration of Azithromycin Dermal Formulation During Repeated Applications on the Skin of Healthy Volunteers|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||November 2010|
|Actual Study Completion Date :||November 2010|
- Drug: Application of SHB001
- Cohort 1: Application of SHB001 on the skin of right thigh
- Application of SHB001 on the skin of right thigh
- punch biopsies of treated skin areas
- 0% SHB001 azitrhomycin dermal formulation (placebo)
- 5% SHB001 azitrhomycin dermal formulation
- 10% SHB001 azitrhomycin dermal formulation
- Local safety [ Time Frame: April 2010 - November 2010 ]The primary objective of this study is to assess the local safety of azithromycin dermal formulation when applied to healthy skin in healthy volunteers. This will be done by determination (in cohort 1) and confirmation (in cohort 2) of the maximal tolerated dose (MTD) after dermal application of SHB001 in 4 different dose regimens.
- Pharmacokinetics of SHB001 [ Time Frame: April 2010 - November 2010 ]
- To assess the pharmacokinetics of azithromycin dermal formulation in the plasma in healthy volunteers after daily administration for three consecutive days in cohort 1 and cohort 2.
- To assess the pharmacokinetics of azithromycin dermal formulation in the skin in healthy volunteers after daily administration for 1 - 3 consecutive days in cohort 2 only.
- To demonstrate that the Minimal Inhibitory Concentration (MIC) of B.b. (=0.03μg/ml) in the skin is reached at least for 2 consecutive assessments (biopsies) in cohort 2.
- To assess general safety in cohort 1 and 2.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01243008
|Clinical Trials Center, University and University Hospital Zurich|
|Zurich, Switzerland, 8091|
|Study Director:||01 Studienregister MasterAdmins||UniversitaetsSpital Zuerich|